NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ETNB

89bio Inc

Jul 01 • 04:00PM ET

9.73

Dollar change -0.09
Percentage change -0.92	%

Healthcare • Biotechnology • USA • NASD

Peers: AKRO MDGL VKTX GNFT CENTA CGEN NBIX GILD VYGR PRTA

| Held by: VTI IWM VXF XBI IBB IWN SCHA VTWO IWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.38	Insider Own	3.20%	Shs Outstand	145.98M	Perf Week	-0.87%
Market Cap	1.42B	Forward P/E	-	EPS next Y	-2.23	Insider Trans	122.08%	Shs Float	141.32M	Perf Month	-1.12%
Enterprise Value	819.22M	PEG	-	EPS next Q	-0.50	Inst Own	106.18%	Short Float	9.90%	Perf Quarter	33.84%
Income	-386.67M	P/S	-	EPS this Y	41.09%	Inst Trans	44.23%	Short Ratio	6.76	Perf Half Y	21.47%
Sales	0.00M	P/B	2.35	EPS next Y	-7.89%	ROA	-61.26%	Short Interest	13.99M	Perf YTD	24.42%
Book/sh	4.15	P/C	2.22	EPS next 5Y	13.99%	ROE	-69.30%	52W High	11.84 -17.82%	Perf Year	29.05%
Cash/sh	4.38	P/FCF	-	EPS past 3/5Y	7.88% 32.21%	ROIC	-60.20%	52W Low	4.16 133.89%	Perf 3Y	180.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.21% 5.25%	Perf 5Y	-57.46%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-68.13%	Oper. Margin	-	ATR (14)	0.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	18.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.63	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	18.03	EPS Q/Q	9.68%	SMA20	-2.88%	Beta	1.51	Target Price	30.30
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	9.04%	Rel Volume	0.93	Prev Close	9.82
Employees	93	LT Debt/Eq	0.06	Earnings	May 01 AMC	SMA200	16.02%	Avg Volume	2.07M	Price	9.73
IPO	Nov 11, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.49% -	Trades		Volume	1,927,848	Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-25	Initiated	Goldman	Neutral	$11
Mar-13-25	Initiated	Citigroup	Buy	$25
Feb-04-25	Initiated	Wolfe Research	Outperform
Apr-22-24	Resumed	BofA Securities	Buy	$30
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $15
Oct-10-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-28-23	Initiated	UBS	Buy	$36
Jun-13-23	Initiated	Evercore ISI	Outperform	$49
May-12-22	Upgrade	Raymond James	Outperform → Strong Buy	$33 → $12
Dec-20-21	Initiated	H.C. Wainwright	Buy	$46
Oct-26-21	Resumed	Cantor Fitzgerald	Overweight	$49
Jul-29-21	Resumed	BTIG Research	Buy	$60
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$65 → $35
Apr-21-21	Initiated	Cantor Fitzgerald	Overweight	$58
Oct-19-20	Initiated	Raymond James	Strong Buy	$65
Sep-25-20	Upgrade	BofA Securities	Neutral → Buy	$37 → $43
Jul-31-20	Initiated	Piper Sandler	Overweight	$54
Jul-23-20	Initiated	BTIG Research	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$58
Dec-09-19	Initiated	SVB Leerink	Outperform

Show Previous Ratings

Jun-06-25 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-25 04:05PM	89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-13-25 08:46AM	Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-09-25 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.32%
May-06-25 04:05PM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.99%
04:05PM	Loading…
May-01-25 04:05PM	89bio Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) +7.38%
Apr-24-25 06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -9.84%
07:00AM	VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study (Zacks)
Apr-08-25 06:55AM	VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe (Zacks) -12.02%
06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
Apr-03-25 10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +5.81%
11:20AM	Loading…
Mar-28-25 11:20AM	FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda (Zacks) -9.82%
Mar-26-25 07:58AM	GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection (Zacks)
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
Mar-25-25 09:40AM	Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year? (Zacks) -12.46%
07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks)
Mar-21-25 01:03PM	Elevation Oncology Plunges 42% on Ending Development of Lead Drug (Zacks)
01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
Mar-13-25 11:34AM	Citi says SMid biotechs alternative to large caps as it starts coverage (Investing.com)
Mar-12-25 09:55AM	Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now (Zacks) +10.74%
Mar-03-25 04:05PM	89bio to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-25 04:05PM	89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire)
Feb-20-25 09:55AM	Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks)
09:55AM	Should You Buy 89BIO (ETNB) After Golden Cross? (Zacks)
Feb-06-25 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 08:00AM	89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
10:31PM	Loading…
Jan-28-25 10:31PM	89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:59PM	Why 89bio Stock Lagged the Market Today (Motley Fool)
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +26.23%
04:12PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-13-25 08:00AM	89bio Provides Business Update and Outlook for 2025 (GlobeNewswire)
Dec-19-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.62% +12.94%
Dec-04-24 01:02PM	Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-29-24 01:30PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:05PM	89bio to Participate in the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-15-24 08:05AM	89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 (GlobeNewswire) -9.37%
Nov-12-24 11:58PM	89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.95%
04:01PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-07-24 04:05PM	89bio Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-05-24 04:05PM	89bio to Participate in the UBS Global Healthcare Conference (GlobeNewswire) +10.18%
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily) +17.48%
Oct-18-24 01:01AM	Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings (GuruFocus.com)
Oct-17-24 01:05PM	State Street Corp's Strategic Acquisition in 89bio Inc (GuruFocus.com)
Oct-15-24 08:30AM	89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-11-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-24 04:05PM	89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference (GlobeNewswire)
Sep-19-24 04:03PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-24 04:05PM	89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer (GlobeNewswire)
Sep-04-24 04:15PM	NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth (GlobeNewswire)
Aug-29-24 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-24 08:00AM	89bio Appoints Francis Sarena as Chief Operating Officer (GlobeNewswire)
Aug-05-24 09:55PM	ETNB Stock Earnings: 89bio Beats EPS for Q2 2024 (InvestorPlace) -5.84% -5.36%
04:05PM	89bio Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
08:00AM	89bio Appoints Charles McWherter, Ph.D., to its Board of Directors (GlobeNewswire)
Jul-12-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
May-22-24 04:05PM	89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress (GlobeNewswire) -8.40%
May-14-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis (GlobeNewswire)
May-10-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:16PM	89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials (GuruFocus.com)
May-09-24 10:54PM	ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 11:56PM	Jump on the Bandwagon, Says Bank of America About These 2 Stock Picks (TipRanks)
04:05PM	89bio to Participate in the BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-06-24 12:00PM	All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy (Zacks)
May-02-24 04:05PM	89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH (GlobeNewswire)
Apr-17-24 04:05PM	89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors (GlobeNewswire)
Apr-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-24 07:01PM	89bio Inc CEO Rohan Palekar Sells 52,718 Shares (GuruFocus.com)
Mar-27-24 08:00AM	89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal) -6.80%
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis (GlobeNewswire)
Mar-08-24 04:05PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-24 01:34PM	Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Crispin Odey, Glen Kacher, Julian Robertson, Nelson Peltz, Brevan Howard Asset Management, SLR Investment Corp. (SLRC), 89bio, Inc. (ETNB), and More (Insider Monkey) +7.34%
Mar-05-24 04:05PM	89bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -14.81%
09:55AM	Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade (Zacks)
09:30AM	89BIO (ETNB) Just Overtook the 200-Day Moving Average (Zacks)
Mar-04-24 04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily) +9.11%
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
Mar-02-24 04:31AM	89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... (GuruFocus.com)
Feb-29-24 04:05PM	89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) +10.03%
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-06-24 04:05PM	89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -17.04%
Feb-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 09:35AM	89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-10-24 09:55AM	Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect? (Zacks)
Dec-19-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.71%
Dec-12-23 07:30AM	89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-07-23 07:00AM	89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-06-23 04:36PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-04-23 07:00AM	89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 (GlobeNewswire) +7.74%
Nov-27-23 08:00AM	89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Le-Nguyen Quoc	See Remarks	Apr 15 '25	Sale	5.95	15,329	91,208	328,323	Apr 17 04:05 PM
QUOC LE-NGUYEN	Officer	Apr 15 '25	Proposed Sale	5.95	15,329	91,171		Apr 15 04:06 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jan 30 '25	Buy	8.75	5,714,285	49,999,994	19,554,319	Feb 03 05:38 PM
McWherter Charles	Director	Jan 22 '25	Buy	6.71	10,000	67,100	25,000	Jan 23 07:38 PM
McWherter Charles	Director	Jan 21 '25	Buy	6.55	5,000	32,750	15,000	Jan 23 07:38 PM
Le-Nguyen Quoc	See Remarks	Jan 15 '25	Sale	6.49	10,963	71,150	271,833	Jan 17 04:01 PM
QUOC LE-NGUYEN	Officer	Jan 15 '25	Proposed Sale	6.49	10,963	71,110		Jan 15 04:13 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 06 '24	Buy	7.89	5,000	39,450	471,236	Dec 10 06:02 AM
McWherter Charles	Director	Dec 05 '24	Buy	8.00	10,000	80,000	10,000	Dec 09 06:01 AM
PALEKAR ROHAN	Chief Executive Officer	Nov 22 '24	Buy	8.35	10,000	83,500	466,236	Nov 25 06:05 AM
Le-Nguyen Quoc	See Remarks	Oct 30 '24	Sale	8.12	27,955	226,995	187,796	Nov 01 04:01 PM
QUOC LE-NGUYEN	Officer	Oct 30 '24	Proposed Sale	8.12	27,955	226,972		Oct 30 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ETNB

89bio Inc

Upgrade your FINVIZ experience